Trump's Executive Order on Drug Prices: International Benchmarking and PBMs

US Drug Pricing vs. International Models

• 💡 The US drug pricing system is a negotiation between pharma companies, insurers, and pharmacy benefit managers (PBMs), unlike government-dictated prices in Europe.
• 🌍 In Europe, governments act as single payers and can negotiate harder, sometimes refusing to offer drugs even at lower prices if they don't meet value assessments.
• ⏳ This can lead to delays in drug availability in Europe, potentially causing companies to prioritize US launches.

Impact of International Price Pegging

• 🎯 A key question is whether pegging US prices to international benchmarks will actually lower costs for Americans or if it benefits pharma companies by increasing global prices.
• 📉 If global prices are forced down, it could reduce revenue for pharmaceutical companies, potentially leading to a decrease in Research and Development (R&D) spending.
• 💰 The transcript questions the realism of expecting lower US prices if the goal is to get the rest of the world to pay more.

The Role of Pharmacy Benefit Managers (PBMs)

• ⚠️ PBMs are identified as middlemen between insurers and drugmakers, and are considered to be at the highest risk from this executive order.
• ❓ The transcript questions the necessity of PBMs, highlighting how drug costs can vary significantly based on insurance plans and states.
• 📉 PBMs' role in negotiating discounts, such as for insulins where reported prices can be 80% lower than list price, is discussed, with a question raised about why they are needed if these savings aren't fully passed on.

Potential for Direct-to-Consumer Sales

• 📈 The administration is exploring ways to allow drugmakers to sell directly to consumers at lower prices, bypassing intermediaries.
• 🇺🇸 Currently, US prices for drugs like Lilly's De Novo are significantly higher than in other markets, with the US price being about twice the European price.
• 🤝 The transcript suggests that the US government needs to incorporate drug pricing into trade agreements to effectively find and enforce international prices, rather than relying on voluntary negotiations or opaque commercial deals.